Search results for "BOC"

showing 10 items of 477 documents

Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: New insights for an old treatment

2022

Although splenectomy is still considered the most effective curative treatment for immune thrombocytopenia (ITP), its use has significantly declined in the last decade, especially since the approval of thrombopoietin receptor agonists (TPO-RAs). The main objective of the study was to determine whether splenectomy was still as effective nowadays, particularly for patients with failure to respond to TPO-RAs. Our secondary objective was to assess, among patients who relapsed after splenectomy, the pattern of response to treatments used before splenectomy. This multicentre retrospective study involved adults who underwent splenectomy for ITP in France from 2011 to 2020. Response status was defi…

AdultMaleThrombopoietin Receptor Agonistsmedicine.medical_specialtymedicine.medical_treatmentSplenectomy[SDV.CAN]Life Sciences [q-bio]/CancerGastroenterology[SDV.CAN] Life Sciences [q-bio]/CancerInternal medicineHumansMedicineRetrospective StudiesPurpura Thrombocytopenic Idiopathicbusiness.industryRetrospective cohort studyHematologyMiddle AgedImmune thrombocytopeniaTreatment OutcomeCurative treatmentSustained responseSplenectomyFemaleRituximabRituximabbusinessReceptors Thrombopoietinmedicine.drugAmerican Journal of Hematology
researchProduct

Continuous intravenous infusion of dipyridamole as adjunctive therapy in the treatment of thrombotic thrombocytopenic purpura.

2003

Abstract Thrombotic thrombocytopenic purpura (TTP) is an uncommon hematologic thrombotic disorder characterized by fever, hemorrhagic and neurologic signs. The advent of plasma exchange has dramatically improved the prognosis of this disease, which was once inevitably fatal. However, mortality rates remain significant. Antiplatelet drugs have been widely used in combination with plasma exchange. In this pilot study we investigated the effects of an adjunctive therapy consisting of the continuous, intravenous infusion of dipyridamole, a modality of administration that has not been previously tested in this setting. Sixteen untreated TTP patients, diagnosed consecutively at our clinic, receiv…

AdultMaleTime FactorsCombination therapyThrombotic thrombocytopenic purpuraPilot ProjectsMethylprednisolonelaw.inventionRandomized controlled trialRefractorylawRecurrencemedicineHumansPlateletIn patientProspective StudiesInfusions IntravenousPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industryPlatelet CountMortality rateRemission InductionHematologyDipyridamoleMiddle Agedmedicine.diseaseCombined Modality TherapyDipyridamoleTreatment OutcomeAnesthesiaFemalebusinessPlatelet Aggregation Inhibitorsmedicine.drugTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
researchProduct

Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience

2007

This study reports the first evaluation of therapeutic response in Romanian patients with Gaucher disease type I, after therapy with Cerezyme recently became available in our country.24 patients (11-50 years) received Cerezyme 20-60 U/kg every two weeks for at least 18 months. Haemoglobin, platelet count, volume of the liver and spleen, plasma chitotriosidase and the severity score were assessed every 6 months; skeletal radiography and osteodensitometry were also monitored.Eleven patients were splenectomized before start of therapy. Eight patients had anaemia (mean haemoglobin 9.4 g/dl) and 14 patients, of whom 13 were without splenectomy, had thrombocytopenia (mean 65,692/mm3). Haemoglobin…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyPediatricsTime FactorsAdolescentBone diseasemedicine.medical_treatmentDiseaseWeight GainSeverity of Illness IndexHemoglobinsGeneticsmedicineHumansIn patientChildGenetics (clinical)ChemotherapyGaucher DiseasePlatelet CountRomaniabusiness.industryLiver DiseasesRomaniannutritional and metabolic diseasesAnemiaEnzyme replacement therapyMiddle Agedmedicine.diseaseCombined Modality TherapyThrombocytopeniaRecombinant Proteinslanguage.human_languageSurgeryHexosaminidasesTreatment OutcomeSplenomegalyQuality of LifeSplenectomylanguageGlucosylceramidaseFemaleBone DiseasesbusinessFollow-Up StudiesJournal of Inherited Metabolic Disease
researchProduct

Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania

2008

Background Studies of antiretroviral therapy (ART) programs in Africa have shown high initial mortality. Factors contributing to this high mortality are poorly described. The aim of the present study was to assess mortality and to identify predictors of mortality in HIV-infected patients starting ART in a rural hospital in Tanzania. Methods This was a cohort study of 320 treatment-naïve adults who started ART between October 2003 and November 2006. Reliable CD4 cell counts were not available, thus ART initiation was based on clinical criteria in accordance with WHO and Tanzanian guidelines. Kaplan-Meier models were used to estimate mortality and Cox proportional hazards models to identify p…

AdultMalemedicine.medical_specialtyAdolescentAnemiaHospitals RuralHIV InfectionsKaplan-Meier EstimateTanzanialcsh:Infectious and parasitic diseasesCohort StudiesRisk FactorsInternal medicinemedicineHumanslcsh:RC109-216Survival analysis:Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin sosialmedisin: 801 [VDP]SurveillanceProportional hazards modelbusiness.industryHazard ratioMalnutritionAnemiaMiddle Agedmedicine.diseasePrognosisSurvival AnalysisThrombocytopenia:Medisinske Fag: 700::Helsefag: 800::Forebyggende medisin: 804 [VDP]SurgeryMalnutritionInfectious DiseasesAnti-Retroviral AgentsFemalebusinessRisk assessmentBody mass indexCohort studyFollow-Up StudiesResearch ArticleBMC Infectious Diseases
researchProduct

Clinical features of oral lichen planus. A retrospective study of 65 cases

2010

Objectives: To describe the clinical features of patients diagnosed with oral lichen planus (OLP) and to establish the prevalence of its malignant transformation in our setting. Study design: A retrospective study was made of 65 patients clinically and histologically diagnosed with OLP in the Service of Oral Surgery (Dental Clinic of the University of Barcelona, Spain) in the period 1990-2005. A descriptive and bivariate statistical analysis was made. Results: The mean patient age was 59 years (SD ± 14.9). Most of the patients (61%) were women, and the most frequent location of the lesions was the buccal mucosa (90.8%). White forms of OLP were noted in 66% of the cases, and 46.2% of the pat…

AdultMalemedicine.medical_specialtyAdolescentLichensAlcohol abuseMalalties de la bocaChronic liver diseaseBuccal mucosaYoung AdultHepatitis víricastomatognathic systemDiabetes mellitusStatistical significanceTabacTobaccomedicineHumansLíquensViral hepatitisGeneral DentistryAgedRetrospective StudiesAged 80 and overbusiness.industryRetrospective cohort studyMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]DermatologySurgerystomatognathic diseasesMouth diseasesOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASPopulation studySurgeryOral lichen planusFemalebusinessLichen Planus Oral
researchProduct

Antimicrobial prophylaxis in patients with immune thrombocytopenia treated with rituximab: a retrospective multicenter analysis

2021

The primary aim of this study was to describe the use of primary anti-infective prophylaxis (AP) in common clinical practice in patients affected by immune thrombocytopenia (ITP) and treated with RTX. Population studied consisted of patients affected by ITP (age ≥ 18 years) who had received at least one dose of RTX from January 2008 to June 2018. Five Italian haematology centres participated in the current study. Data were retrospectively collected: demographic data (age, gender), concomitant comorbidities and previous therapies for ITP, characteristics of AP, the occurrence of infections and their management. The ITP cohort consisted of 67 patients sub-grouped into two categories according…

AdultMalemedicine.medical_specialtyAdolescentPopulationOpportunistic InfectionsPneumocystis pneumoniaYoung Adult03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansPractice Patterns Physicians'educationAgedRetrospective StudiesAged 80 and overPurpura Thrombocytopenic Idiopathiceducation.field_of_studyHematologybusiness.industrySulfamethoxazoleHematologyGeneral MedicineAntibiotic ProphylaxisMiddle Agedmedicine.diseaseTrimethoprimItaly030220 oncology & carcinogenesisConcomitantCohortFemaleRituximabImmune thrombocytopenia . Rituximab . Antimicrobial prophylaxis . InfectionsRituximabbusiness030215 immunologymedicine.drugAnnals of Hematology
researchProduct

Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab.

2018

Background Autoimmune thrombotic thrombocytopenic purpura (iTTP) is caused by autoantibody-mediated severe a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13 (ADAMTS13) deficiency leading to micro-angiopathic haemolytic anaemia (MAHA) and thrombocytopenia with organ damage. Patients survive with plasma exchange (PEX), fresh frozen plasma replacement and corticosteroid treatment. Anti-CD20 monoclonal antibody rituximab is increasingly used in patients resistant to conventional PEX or relapsing after an acute bout. Objective This retrospective observational study focused on the relapse rate and possible influencing factors including treatment with rituximab first…

AdultMalemedicine.medical_specialtyAdolescentautoantibodiesThrombotic thrombocytopenic purpuraADAMTS13 ProteinRelapse rate030204 cardiovascular system & hematologyGastroenterologyAutoimmune Diseases03 medical and health sciencesYoung Adult0302 clinical medicineSex FactorsRecurrenceInternal medicinehemic and lymphatic diseasesCellular Haemostasis and PlateletsMedicineHumansImmunologic Factorsclinical studiesYoung adultChildADAMS/ADAMTS13Retrospective StudiesPurpura Thrombotic Thrombocytopenicbusiness.industryRetrospective cohort studyHematologythrombotic thrombocytopenic purpura (TTP/HUS)Middle Agedmedicine.diseaseAntigens CD20ADAMTS13PurpuraTreatment Outcome030220 oncology & carcinogenesisRituximabFemaleFresh frozen plasmamedicine.symptombusinessRituximabmedicine.drugFollow-Up StudiesThrombosis and haemostasis
researchProduct

A pioneering epidemiological study investigating the incidence of squamous cell carcinoma of tongue in a Portuguese population

2012

Objective: The purpose of this study was to investigate the incidence of squamous cell carcinoma (SCC) of the anterior two thirds of the tongue in a population living in central and southern Portugal, all treated at Portuguese Institute of Oncology of Lisbon, Francisco Gentil (IPOLFG). Study Design: This study was a retrospective review of all patients who had a histopathological diagnosis of SCC of the anterior two thirds of the tongue and had been treated in the Head and Neck Surgery Unit at the IPOLFG (Lisbon, Portugal), between 1st January 2001 and 31st December 2009. The risk factors evaluated were: gender; age; alcohol consumption; tobacco use; prosthesis use and the carcinoma site. R…

AdultMalemedicine.medical_specialtyCancer cellsPopulationYoung AdultTongueEpidemiologyCarcinomamedicineHumansTongue NeoplasmeducationGeneral DentistryAgedRetrospective StudiesAged 80 and overMoutheducation.field_of_studyOral Medicine and PathologyPortugalPortuguesebusiness.industryIncidenceBocaIncidence (epidemiology)Retrospective cohort studyMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseTongue NeoplasmsPortuguesosSurgerymedicine.anatomical_structureOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASCarcinoma Squamous CellEtiologyResearch-ArticleFemaleCèl·lules cancerosesSurgerybusinessDemographyMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Home parenteral nutrition-associated thromboembolic and bleeding events: results of a cohort study of 236 individuals

2016

UNLABELLED Essentials Sparse or outdated studies focus on thrombotic and bleeding risk in home parenteral nutrition (HPN). 236 HPN patients followed at a single center for a total of 684 patient-years were evaluated. Rates of venous thrombosis and major bleeding, and prevalence of vena cava syndrome are provided. Anticoagulants might reduce thrombosis risk, but population-specific safety concerns remain. SUMMARY Background Home parenteral nutrition (HPN) is necessary for patients with intestinal failure. Recurrent catheter-related thrombosis (CRT) is common, leading to infectious complications, pulmonary embolism, vascular access loss and intestinal transplantation. The efficacy and safety …

AdultMalemedicine.medical_specialtyCatheterization Central VenousSuperior Vena Cava SyndromeHemorrhage030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineThromboembolismmedicineHumans030212 general & internal medicineProportional Hazards ModelsRetrospective Studiesbusiness.industryHeparinHazard ratioAnticoagulantsRetrospective cohort studyThrombosisHematologyVenous ThromboembolismMiddle Agedmedicine.diseaseThrombosisThrombocytopeniaPulmonary embolismSurgeryTransplantationVenous thrombosisParenteral nutritionTreatment OutcomeFemalebusinessParenteral Nutrition HomePulmonary EmbolismCohort study
researchProduct

Baseline characteristics and outcome in Romanian patients with Gaucher disease type 1.

2009

Abstract Background/aim To present clinical and genetic characteristics of all Romanian patients with Gaucher disease type 1, in whom specific diagnosis has been confirmed by enzymatic and molecular methods and to analyze their outcome with and without enzymatic replacement therapy (ERT). Patients, methods There are fifty patients (F/M — 1.63/1) with Gaucher disease type 1. Clinical status, haemoglobin, thrombocytes, hepatic/splenic volume, bone mineral density and severity score were assessed at baseline and every six months thereafter. Thirty-nine patients (78%) received imiglucerase (44.4 ± 13.6 U/kg/2 weeks) for 3.1 +/− 1.4 years. Results Based on general prevalence data, our group repr…

AdultMalemedicine.medical_specialtyEvery Six MonthsBone diseaseImigluceraseAdolescentGenotypeDiseaseGastroenterologyYoung AdultInternal medicineGenotypeInternal MedicinemedicineHumansPlateletAge of OnsetChildAllelesBone mineralGaucher Diseasebusiness.industryRomaniaInfantAnemiaMiddle Agedmedicine.diseasePrognosisThrombocytopeniaSurgeryHexosaminidasesChild PreschoolMutationSplenomegalyGlucosylceramidaseFemalebusinessVisceromegalymedicine.drugEuropean journal of internal medicine
researchProduct